Quince Therapeutics (QNCX) Assets Average (2019 - 2026)

Quince Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $60.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 45.77% year-over-year to $60.1 million; the TTM figure through Mar 2026 stood at $60.1 million (down 45.77% YoY), while the FY2025 annual figure was $104.0 million, down 26.34% from the prior year.
• Assets Average for Q1 2026 stood at $60.1 million, down from $101.7 million in the prior quarter.
• The five-year high for Assets Average was $163.6 million in Q1 2024, with the low at $60.1 million in Q1 2026.
• The 5-year median for Assets Average is $113.6 million (2025), against an average of $113.3 million.
• The sharpest annual moves came in 2024 and 2026: Assets Average jumped 65.9% in 2024, then slumped 45.77% in 2026.
• Quince Therapeutics' Assets Average stood at $106.8 million in 2022, then climbed by 18.53% to $126.6 million in 2023, then fell by 4.85% to $120.5 million in 2024, then dropped by 15.59% to $101.7 million in 2025, then plunged by 40.94% to $60.1 million in 2026.
• Business Quant data shows QNCX's Assets Average at $60.1 million in Q1 2026, $101.7 million in Q4 2025, and $113.6 million in Q3 2025.